CPT® Code 86821

1. Indications

HLA typing using mixed lymphocyte culture (MLC) is indicated for several specific clinical scenarios, including:

• Transplant Compatibility HLA typing is performed to determine the tissue compatibility between a potential donor and recipient for stem cell, bone marrow, or solid organ transplants.
• Susceptibility to Disease Testing for specific HLA alleles helps identify individuals who may be genetically predisposed to certain diseases, aiding in risk assessment and management.

2. Procedure

The procedure for HLA typing using mixed lymphocyte culture involves several key steps, which are detailed as follows:

• Step 1: Sample Collection Blood samples are collected from both the donor and the recipient. These samples contain lymphocytes, which are the white blood cells used in the MLC process.
• Step 2: Cell Preparation The lymphocytes from the blood samples are purified to isolate the responder cells. This purification process ensures that only the relevant lymphocyte populations are used in the culture.
• Step 3: Stimulation Setup The purified responder lymphocytes are mixed with prepared stimulator cells that are homozygous for specific HLA antigens. This mixture creates a controlled environment for the cells to interact.
• Step 4: Culture Incubation The mixed lymphocyte culture is incubated under specific conditions that promote cellular proliferation. This incubation period allows the responder cells to react to the stimulator cells.
• Step 5: Response Measurement After the incubation period, the cellular response is measured. The degree of proliferation of the responder cells indicates compatibility; a lack of response suggests that the cells are compatible, while a significant response indicates incompatibility.

3. Post-Procedure

After the mixed lymphocyte culture procedure, the results are analyzed to determine the compatibility between the donor and recipient. The findings are crucial for making informed decisions regarding transplantation. If the cells are found to be compatible, it may proceed with the transplant process. If incompatibility is indicated, alternative donor options may need to be considered. Additionally, the laboratory may provide recommendations for further testing or monitoring based on the results. It is essential for healthcare providers to communicate the results to the patients and discuss the implications for their treatment plans.